SciELO - Scientific Electronic Library Online

vol.35 número4 índice de autoresíndice de materiabúsqueda de artículos
Home Pagelista alfabética de revistas  

Servicios Personalizados



Links relacionados

  • En proceso de indezaciónCitado por Google
  • No hay articulos similaresSimilares en SciELO
  • En proceso de indezaciónSimilares en Google


Actas Urológicas Españolas

versión impresa ISSN 0210-4806


MOROTE, J.  y  PLANAS, J.. Pérdida de masa ósea en pacientes con cáncer de próstata sometidos a deprivación androgénicaLoss of bone mass in patients with prostate cancer subjected to androgenic deprivation. Actas Urol Esp [online]. 2011, vol.35, n.4, pp.232-239. ISSN 0210-4806.

Context: Treatment based on androgenic deprivation is one of the standard treatments that many prostate cancer patients receive. Moreover, its use is increasing due to a clear expansion of the indications of this therapy in patients with localized cancer. Summary of evidence: In spite of being classically considered that it is well tolerated, androgenic deprivation has adverse effects. Of these, it is worth mentioning the loss of mineral bone mass, which can lead to osteoporosis and increase the risk of bone fracture. Some fractures may have serious consequences, as occurs with hip fractures. To make a diagnosis in this situation, there are useful procedures such as bone densitometry. Once diagnosed, the decrease in mineral bone mass can be managed with dietary recommendations, general changes in lifestyle, or with drugs such as denosumab. Conclusions: Following applicable recommendations, urologists must carefully monitor the bone health of patients with prostate cancer subjected to androgenic deprivation, in order to obtain an early diagnosis and to apply the appropriate general and/or therapeutic measures, if necessary.

Palabras clave : Prostate cance; Androgenic deprivation; Bone densitometry; Osteoporosis; Bisphosphonates; Denosumab.

        · resumen en Español     · texto en Español     · Español ( pdf )


Creative Commons License Todo el contenido de esta revista, excepto dónde está identificado, está bajo una Licencia Creative Commons